[{"id":"8551971c-dc39-40b0-a802-ab21b9ec4738","acronym":"","url":"https://clinicaltrials.gov/study/NCT07188740","created_at":"2025-09-27T08:44:07.719Z","updated_at":"2025-09-27T08:44:07.719Z","phase":"Phase 1","brief_title":"Metformin Inhibits DNMT3A Clonal Hematopoiesis in Acute Leukemia","source_id_and_acronym":"NCT07188740","lead_sponsor":"Institute of Hematology \u0026 Blood Diseases Hospital, China","biomarkers":" DNMT3A","pipe":"","alterations":" ","tags":["DNMT3A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/30/2025","start_date":" 10/30/2025","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 08/30/2029","study_completion_date":" 08/30/2029","last_update_posted":"2025-09-23"},{"id":"3ed2719e-561e-41cf-943c-89926f1e9bc8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05306028","created_at":"2023-12-15T20:17:43.728Z","updated_at":"2025-02-25T13:40:56.951Z","phase":"Phase 2","brief_title":"Metformin and Insulin to Pancreatic Cancer Related Diabetes (Type 3c)","source_id_and_acronym":"NCT05306028","lead_sponsor":"Fudan University","biomarkers":" CA 19-9","pipe":"","alterations":" ","tags":["CA 19-9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-21"},{"id":"fc853ccb-9f4e-4599-bd19-d2d6e2520e4f","acronym":"","url":"https://clinicaltrials.gov/study/NCT06044025","created_at":"2023-11-29T19:16:19.395Z","updated_at":"2025-02-25T16:40:12.563Z","phase":"Phase 1","brief_title":"A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy","source_id_and_acronym":"NCT06044025","lead_sponsor":"University of Arkansas","biomarkers":" TGFB1","pipe":"","alterations":" ","tags":["TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 04/11/2024","start_date":" 04/11/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2025-02-06"},{"id":"6a7e2afb-013b-43d3-b31e-6052a197be35","acronym":"met-HEReMYTA","url":"https://clinicaltrials.gov/study/NCT02488564","created_at":"2021-01-18T11:59:22.933Z","updated_at":"2025-02-25T16:58:50.319Z","phase":"Phase 2","brief_title":"A Study of Liposomal Doxorubicin+Docetaxel+Trastuzumab+Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer","source_id_and_acronym":"NCT02488564 - met-HEReMYTA","lead_sponsor":"Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • docetaxel • metformin • Myocet (non-pegylated liposomal doxorubicin) • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 49","initiation":"Initiation: 12/17/2014","start_date":" 12/17/2014","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 03/17/2020","study_completion_date":" 03/17/2020","last_update_posted":"2025-02-03"},{"id":"2b3b95d5-ea57-4c3b-b692-eadad885ae68","acronym":"GO39374","url":"https://clinicaltrials.gov/study/NCT03006172","created_at":"2021-01-17T17:17:17.326Z","updated_at":"2025-02-25T12:26:36.051Z","phase":"Phase 1","brief_title":"To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer","source_id_and_acronym":"NCT03006172 - GO39374","lead_sponsor":"Genentech, Inc.","biomarkers":" HER-2 • PIK3CA","pipe":" | ","alterations":" HER-2 negative • PIK3CA mutation","tags":["HER-2 • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Ibrance (palbociclib) • Perjeta (pertuzumab) • fulvestrant • letrozole • metformin • Itovebi (inavolisib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 12/13/2016","start_date":" 12/13/2016","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-12-20"},{"id":"34985820-886b-4e61-90e7-8b16e17a8048","acronym":"MEMENTO","url":"https://clinicaltrials.gov/study/NCT06687876","created_at":"2025-02-25T19:17:34.383Z","updated_at":"2025-02-25T19:17:34.383Z","phase":"Phase 2","brief_title":"Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy","source_id_and_acronym":"NCT06687876 - MEMENTO","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" CD163","pipe":"","alterations":" ","tags":["CD163"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 12/01/2024","start_date":" 12/01/2024","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-11-18"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"89176c1c-27c2-481c-88e1-d9f4d154f90c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03800602","created_at":"2021-01-18T18:47:18.063Z","updated_at":"2025-02-25T14:27:58.209Z","phase":"Phase 2","brief_title":"Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer","source_id_and_acronym":"NCT03800602","lead_sponsor":"Emory University","biomarkers":" EGFR","pipe":" | ","alterations":" RAS wild-type","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • metformin"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 01/15/2019","start_date":" 01/15/2019","primary_txt":" Primary completion: 09/04/2020","primary_completion_date":" 09/04/2020","study_txt":" Completion: 09/04/2021","study_completion_date":" 09/04/2021","last_update_posted":"2024-09-05"},{"id":"013fa224-7354-475f-bf22-774d9ee304d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03675893","created_at":"2021-01-18T18:01:44.633Z","updated_at":"2024-07-02T16:34:27.103Z","phase":"Phase 2","brief_title":"RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer","source_id_and_acronym":"NCT03675893","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" ER","pipe":" | ","alterations":" ER positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • letrozole • zotatifin (eFT226) • metformin • samotolisib (LY3023414)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 12/24/2018","start_date":" 12/24/2018","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2029","study_completion_date":" 08/01/2029","last_update_posted":"2024-06-11"},{"id":"03271227-2174-4789-a946-4de77e418a64","acronym":"","url":"https://clinicaltrials.gov/study/NCT04850846","created_at":"2021-04-20T14:55:37.601Z","updated_at":"2024-07-02T16:34:37.692Z","phase":"Phase 2","brief_title":"Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma","source_id_and_acronym":"NCT04850846","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" IGH","pipe":"","alterations":" ","tags":["IGH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/27/2021","start_date":" 04/27/2021","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-06-06"},{"id":"d6f4d9db-9fa8-4c27-a1fe-5ae416df1f5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339168","created_at":"2021-04-26T09:52:48.407Z","updated_at":"2025-02-25T15:33:19.366Z","phase":"Phase 1","brief_title":"Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer","source_id_and_acronym":"NCT02339168","lead_sponsor":"University of California, Davis","biomarkers":" TNFRSF11A","pipe":"","alterations":" ","tags":["TNFRSF11A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/22/2016","start_date":" 06/22/2016","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-05-08"},{"id":"31b173a2-7403-4225-a873-8d7a9822147b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03311308","created_at":"2021-01-18T16:21:14.438Z","updated_at":"2025-02-25T16:06:59.934Z","phase":"Phase 1","brief_title":"A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma","source_id_and_acronym":"NCT03311308","lead_sponsor":"Yana Najjar","biomarkers":" BRAF","pipe":" | ","alterations":" TILs","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TILs"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/07/2018","start_date":" 02/07/2018","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-05-07"},{"id":"41b01b41-ccaf-44d0-9901-ee4360f0dfd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05828303","created_at":"2023-04-25T14:03:37.911Z","updated_at":"2024-07-02T16:35:10.118Z","phase":"Phase 1","brief_title":"A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05828303","lead_sponsor":"Turning Point Therapeutics, Inc.","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Augtyro (repotrectinib) • metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/28/2024","start_date":" 06/28/2024","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-04-11"},{"id":"07dd2c51-fe99-4c3c-9b0a-e4eabf4a89d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT01905046","created_at":"2021-01-18T08:34:52.124Z","updated_at":"2024-07-02T16:35:10.772Z","phase":"Phase 3","brief_title":"Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer","source_id_and_acronym":"NCT01905046","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA mutation","tags":["BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 161","initiation":"Initiation: 11/23/2015","start_date":" 11/23/2015","primary_txt":" Primary completion: 11/10/2023","primary_completion_date":" 11/10/2023","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-04-09"},{"id":"d77b6c89-cb48-4369-b0dc-51bba650225a","acronym":"LACC-MET","url":"https://clinicaltrials.gov/study/NCT06353061","created_at":"2024-04-08T18:25:19.565Z","updated_at":"2024-07-02T16:35:11.016Z","phase":"Phase 2","brief_title":"Chemoradiotherapy With or Without Metformin in Locally Advanced Cervical Cancer","source_id_and_acronym":"NCT06353061 - LACC-MET","lead_sponsor":"Peking Union Medical College Hospital","biomarkers":" CA9","pipe":"","alterations":" ","tags":["CA9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 04/15/2024","start_date":" 04/15/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-08"},{"id":"1313c77f-67b2-4152-a25f-375ac9becf7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT06215976","created_at":"2024-01-22T19:20:11.478Z","updated_at":"2024-07-02T16:35:22.725Z","phase":"Phase 4","brief_title":"The Nephroprotective Effect of Metformin With Cisplatin in Bladder Cancer","source_id_and_acronym":"NCT06215976","lead_sponsor":"Cairo University","biomarkers":" LCN2","pipe":"","alterations":" ","tags":["LCN2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 78","initiation":"Initiation: 06/01/2023","start_date":" 06/01/2023","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-01-22"},{"id":"a29f772a-28b4-49df-8818-8c35ea1c0c0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05929495","created_at":"2023-07-03T16:10:46.484Z","updated_at":"2024-07-02T16:35:29.842Z","phase":"Phase 2","brief_title":"Phase 2, Open-label, Single-arm Study on the Use of Metformin as Adjunctive Therapy in High-grade Glioma","source_id_and_acronym":"NCT05929495","lead_sponsor":"University of Milano Bicocca","biomarkers":" MGMT","pipe":" | ","alterations":" IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-11-09"},{"id":"c5d4896d-d6e6-484b-a31f-c6032c673747","acronym":"","url":"https://clinicaltrials.gov/study/NCT05183204","created_at":"2022-01-10T14:58:24.578Z","updated_at":"2024-07-02T16:35:35.748Z","phase":"Phase 2","brief_title":"Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma","source_id_and_acronym":"NCT05183204","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin • paxalisib (GDC-0084)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 02/14/2022","start_date":" 02/14/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-09-26"},{"id":"b7eeda1c-4953-4b53-929a-d79044662260","acronym":"CCTG MA32","url":"https://clinicaltrials.gov/study/NCT01101438","created_at":"2021-01-18T04:21:28.818Z","updated_at":"2024-07-02T16:35:37.413Z","phase":"Phase 3","brief_title":"A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer","source_id_and_acronym":"NCT01101438 - CCTG MA32","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" HER-2 • PGR • IGF1","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification • HER-2 negative","tags":["HER-2 • PGR • IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Completed","enrollment":" Enrollment 3649","initiation":"Initiation: 08/13/2010","start_date":" 08/13/2010","primary_txt":" Primary completion: 09/21/2021","primary_completion_date":" 09/21/2021","study_txt":" Completion: 08/18/2023","study_completion_date":" 08/18/2023","last_update_posted":"2023-09-12"},{"id":"2bab9c7d-960f-48ce-83cf-ed84479f7a0e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01750567","created_at":"2021-01-18T07:40:45.979Z","updated_at":"2024-07-02T16:35:38.532Z","phase":"Phase 2","brief_title":"A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL","source_id_and_acronym":"NCT01750567","lead_sponsor":"University of Michigan Rogel Cancer Center","biomarkers":" CD20 • CD5 • FCER2","pipe":" | ","alterations":" CD20 positive • Chr del(11q)","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • Chr del(11q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 05/01/2024","primary_completion_date":" 05/01/2024","study_txt":" Completion: 05/01/2024","study_completion_date":" 05/01/2024","last_update_posted":"2023-08-31"},{"id":"bb23c9d2-5b49-4b1a-9605-371d2ef84038","acronym":"","url":"https://clinicaltrials.gov/study/NCT02122185","created_at":"2021-01-18T09:49:52.228Z","updated_at":"2024-07-02T16:35:38.881Z","phase":"Phase 2","brief_title":"Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT02122185","lead_sponsor":"University of Chicago","biomarkers":" CEACAM5 • MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["CEACAM5 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Suspended","enrollment":" Enrollment 160","initiation":"Initiation: 02/25/2015","start_date":" 02/25/2015","primary_txt":" Primary completion: 02/25/2025","primary_completion_date":" 02/25/2025","study_txt":" Completion: 02/25/2025","study_completion_date":" 02/25/2025","last_update_posted":"2023-08-28"},{"id":"c993e922-769f-409a-a31b-b63aa71e12df","acronym":"","url":"https://clinicaltrials.gov/study/NCT04741945","created_at":"2023-08-01T20:09:13.865Z","updated_at":"2024-07-02T16:35:41.527Z","phase":"Phase 2","brief_title":"Repurposing Metformin as a Leukemia-preventive Drug in CCUS and LR-MDS","source_id_and_acronym":"NCT04741945","lead_sponsor":"Kirsten Grønbæk","biomarkers":" TMB","pipe":"","alterations":" ","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/13/2021","start_date":" 12/13/2021","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-08-01"},{"id":"3dd4e9d1-bbeb-4371-9bec-0586bc49931e","acronym":"METLUNG","url":"https://clinicaltrials.gov/study/NCT05445791","created_at":"2022-07-06T15:54:42.611Z","updated_at":"2024-07-02T16:35:44.678Z","phase":"Phase 3","brief_title":"Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations","source_id_and_acronym":"NCT05445791 - METLUNG","lead_sponsor":"Instituto Nacional de Cancerologia de Mexico","biomarkers":" STK11 • AMPK","pipe":" | ","alterations":" EGFR mutation","tags":["STK11 • AMPK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 312","initiation":"Initiation: 07/15/2021","start_date":" 07/15/2021","primary_txt":" Primary completion: 07/14/2024","primary_completion_date":" 07/14/2024","study_txt":" Completion: 07/14/2025","study_completion_date":" 07/14/2025","last_update_posted":"2023-06-27"},{"id":"bb9997f0-453a-4083-9fab-d8017d881de5","acronym":"1R01CA172444-01A1","url":"https://clinicaltrials.gov/study/NCT02028221","created_at":"2021-01-18T09:17:16.755Z","updated_at":"2024-07-02T16:35:44.648Z","phase":"Phase 2","brief_title":"Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk","source_id_and_acronym":"NCT02028221 - 1R01CA172444-01A1","lead_sponsor":"University of Arizona","biomarkers":" IGF1 • IGF2 • IGFBP3 • LEP","pipe":"","alterations":" ","tags":["IGF1 • IGF2 • IGFBP3 • LEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin"],"overall_status":"Completed","enrollment":" Enrollment 151","initiation":"Initiation: 03/07/2014","start_date":" 03/07/2014","primary_txt":" Primary completion: 11/30/2018","primary_completion_date":" 11/30/2018","study_txt":" Completion: 06/14/2022","study_completion_date":" 06/14/2022","last_update_posted":"2023-06-27"}]